Anotrit

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anotrit

Property Description
Active Ingredient Diltiazem hydrochloride
Primary Forms Tablet, Extended-Release Capsule, Solution (Injection)
Pharmacological Class Calcium Channel Blocker (CCB)
Origin Synthetic (Benzothiazepine derivative)
General Purpose Regulating heart function and blood pressure

Anotrit: Definition and Pharmacological Classification

Anotrit is a prescription-only synthetic medication whose active pharmaceutical ingredient is Diltiazem hydrochloride. It belongs to the Calcium Channel Blocker (CCB) pharmacological class, specifically identified as a non-dihydropyridine benzothiazepine derivative. This classification defines its core function as a Class IV antiarrhythmic agent that primarily modulates heart function and blood vessel tone. The substance is structurally and functionally distinct from other CCBs, such as dihydropyridine types, because of its pronounced influence on the heart's electrical conduction system. Diltiazem affects both the heart's rate and its vascular tone.

Composition, Forms, and Origin

The core component of Anotrit is Diltiazem hydrochloride, a synthetic compound. Anotrit is manufactured as a single active ingredient product for systemic treatment and is available in multiple oral dosage forms, including the immediate-release tablet and the extended-release capsule (controlled-release or CD formulation). The extended-release formulations are often clinically recognized for their benefit in promoting sustained therapeutic action over a prolonged period, aiding in long-term management. Beyond oral administration, formulations also exist for intravenous injection, as well as topical preparations.

General Therapeutic Role

The general therapeutic purpose of Anotrit is to stabilize cardiovascular function by influencing the passage of calcium ions into specific heart and vascular smooth muscle cells. This action promotes the relaxation and widening of blood vessels, resulting in vasodilation, which helps facilitate improved blood flow. This pharmacological mechanism supports the medicine's role in the maintenance of appropriate blood pressure levels and the promotion of a more stable heart rhythm. The overall effect is a reduction in myocardial oxygen demand, effectively lessening the heart's workload.

What side effects are possible with Anotrit?

Anotrit's safety profile, based on regulatory documentation, outlines specific adverse reactions and official safety constraints.

Documented Adverse Reactions

Side effects are classified by frequency as observed in clinical data. Common reactions (occurring in 1% to 10% of users) typically include headache, dizziness, swelling of the lower limbs (peripheral edema), a slowed heart rate (bradycardia), first-degree AV block, and constipation. Uncommon reactions may include nervousness, insomnia, and elevations in liver enzyme levels, which are documented under Hepatobiliary Disorders.

Official labels group effects by the affected physiological system, including Cardiac Disorders, Vascular Disorders, Gastrointestinal Disorders, and Skin and Subcutaneous Tissue Disorders.

Serious Safety Considerations

The most clinically significant adverse reactions explicitly documented in regulatory texts include the development of second- or third-degree AV block (a serious cardiac conduction issue) and the worsening of existing congestive heart failure. Rare but serious reactions, such as acute hepatic injury and severe blistering skin conditions (e.g., Stevens-Johnson syndrome), are also noted in post-marketing data.

Population and Usage Constraints

Official prescribing information specifies certain conditions where Anotrit should not be used. These safety restrictions include the presence of sick sinus syndrome or higher-degree AV block unless the individual has a functioning ventricular pacemaker. Caution is noted for populations with impaired hepatic or renal function and for older adults. Furthermore, the label notes that acute hepatic injury has generally been reported early after therapy initiation (within the first 1–8 weeks).

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes overdose with Anotrit (Diltiazem Hydrochloride) as presenting with severe cardiovascular manifestations, requiring immediate medical attention for specialized support.

Documented Overdose Manifestations

An overdose or exaggerated response is officially documented to present with serious alterations in heart function and blood pressure, including bradycardia (abnormally slow heart rates), hypotension (decreases in blood pressure), and high-degree AV block (second- or third-degree atrioventricular block).

Severe Outcomes and Emergency Actions

The most severe documented outcomes include cardiac failure and fixed high-degree AV block. Immediate medical attention is required for these life-threatening events, which necessitate the prompt administration of appropriate supportive measures, as specified in regulatory labeling.

Official Management Profile

No specific antidote is documented for Anotrit overdose. Management focuses on reversing the severe effects using procedures and pharmacological agents listed in official labeling, such as cardiac pacing, inotropic agents (like dopamine or dobutamine), and vasopressors for severe hypotension. Patients must be monitored for signs of hypercalcemia if intravenous calcium is administered as part of the supportive treatment regimen. The regulatory information states that the toxic dose in humans is not known.

Therapeutic Uses of Anotrit

What Anotrit Treats: Main Uses and Benefits

Anotrit is considered relevant for easing symptoms that interfere with daily comfort and is commonly used to help with conditions that create noticeable physiological strain on the heart and vascular system, focusing on three core therapeutic domains: managing sustained high blood pressure (hypertension), managing recurring chest discomfort (angina pectoris), and helping to manage certain rapid heart rhythms (tachyarrhythmias). The medication is commonly applied in clinical settings where supportive symptom management is appropriate for these conditions.

The medication may be relevant for easing symptom clusters that may become intense or disruptive, such as episodes of exertion-related chest pain, asymptomatic but persistent elevation of blood pressure, and sudden fluctuations in heart rate. It provides supportive relief that helps ease the overall symptom burden associated with rhythm instability and supports general well-being during symptomatic phases. It is relevant for easing symptoms that interfere with daily comfort and **may assist with maintaining functional stability.


Quick Fact: Relief for Cardiovascular Strain Anotrit is commonly used to help manage the chronic challenges of high blood pressure and the episodic discomfort of angina, supporting patients during phases of increased physiological stress.

Regulatory References

  1. DailyMed official labeling overview

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Anotrit?

Regulatory documents define strict population eligibility criteria for the use of Anotrit (Diltiazem hydrochloride), primarily based on the patient's existing cardiac conduction status and overall stability.

Contraindications (Must Not Use)

Population Group Condition/Status
Cardiac Conduction Defect Second- or Third-Degree Atrioventricular (AV) Block, or Sick Sinus Syndrome (unless a functioning ventricular pacemaker is present)
Acute Instability Severe Hypotension (systolic BP < 90 mmHg), Cardiogenic Shock, or Acute Myocardial Infarction complicated by pulmonary congestion
Specific Arrhythmias Atrial Fibrillation or Flutter when associated with an accessory bypass tract (e.g., Wolff-Parkinson-White Syndrome)

Restricted or Conditional Use

Use requires caution and monitoring in patients with certain conditions:

  • Organ Impairment: Patients with pre-existing hepatic or renal impairment.
  • Cardiac Function: Individuals with impaired ventricular function or Congestive Heart Failure.

Age and Reproductive Limitations

The medicine is generally not recommended for use in pediatric patients (under 18 years of age) as safety and efficacy have not been established. Use is also not recommended or is contraindicated during pregnancy and lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Anotrit (Diltiazem) has officially documented interaction patterns based on its roles as a cardiac modulator and a pharmacokinetic modifier, as detailed in regulatory documents.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substances/Classes Official Regulatory Outcome/Restriction
Formal Contraindication Intravenous Beta-Blockers Co-administration is formally contraindicated due to risk of severe cardiac depression.
PD Additive Effects Oral Beta-Blockers, Digitalis (Digoxin) Additive effects on heart rate and conduction, increasing risk for bradycardia and AV block.
PK Inhibition CYP3A4 Substrates (e.g., Statins, Cyclosporine) Anotrit is a moderate CYP3A4 and P-gp inhibitor, which increases the exposure of co-administered medicines, such as Simvastatin and Cyclosporine.

Interaction-Related Restrictions and Constraints

Regulatory labeling requires specific restrictions for co-use. Concomitant use with Ivabradine must be avoided. Due to the risk of increased exposure, the dose of co-administered Simvastatin must be limited to 10 mg daily. Similarly, the dose of Ranolazine must be limited to 500 mg twice daily when co-administered. Furthermore, the consumption of Grapefruit juice may increase Anotrit’s plasma levels, while the herbal product St. John’s Wort can officially decrease its concentrations.

Mechanism of Action

Anotrit, containing Diltiazem hydrochloride, exerts its action by acting as a highly specific inhibitor of the L-type slow voltage-dependent calcium channel ( CaV1.2) . This molecular mechanism results in two primary, simultaneous physiological consequences that define its mechanism of action.


Modulation of Cardiac Conduction and Rhythm

This domain covers the drug's effect on the heart's electrical system, where it blocks Ca^2+ channels primarily in the Atrioventricular (AV) node. This action slows the speed of signal propagation, a negative dromotropic effect, and leads to a reduction in the frequency of electrical impulses by prolonging the time between them.


Regulation of Vascular Tone and Myocardial Consumption

The same Ca^2+ channel blockade occurs in vascular smooth muscle cells lining the coronary and peripheral arteries. By limiting the calcium necessary for contraction, the mechanism induces arterial smooth muscle relaxation (vasodilation). This physical widening of the vessels decreases systemic resistance, which results in a reduction in the mechanical load on the heart muscle and decreases myocardial oxygen consumption.

Dosage and Administration Information

Instruction Map: How to use Anotrit — Administration Guidelines

This section outlines the standardized usage requirements for Anotrit (Diltiazem hydrochloride), detailing the administration routes, dosage schedules, and specific handling procedures.

Administration Scope

Property Description
Route of Administration Primarily Oral (immediate- and extended-release forms) and Intravenous (IV). A topical formulation is also available for specialized use.
Dosing Schedule (Regimens) Oral ER: Initial dose typically 180 mg to 240 mg once daily, with titration up to a maximum of 540 mg daily for certain formulations. Oral IR: Initial dose 30 mg four times daily, with maintenance doses taken in divided daily amounts.
Frequency and Titration Extended-release forms are dosed once daily. Dose adjustments for oral therapy are typically performed gradually, often over 7 to 14 days, to reach a stable maintenance level.
Timing in Relation to Meals Varies by specific formulation: some Extended-Release tablets can be taken without regard to food, while other capsules may be advised on an empty stomach.
Age-Group Rules For older adults or patients with impaired kidney/liver function, guidelines suggest initiation at a lower starting dose (e.g., 120 mg once daily) with careful, slow titration. Use in pediatric patients is not established or recommended.
Missed-Dose Rules If an oral dose is missed, skip the missed dose and resume the regular schedule; doses should not be doubled.

Resulting Procedural Structure

Procedural sequence and handling constraints:

  • Administer the oral dose at the required frequency (once or multiple times daily).
  • Extended-release tablets and capsules must be swallowed whole and must not be crushed, chewed, or divided to maintain the drug’s controlled release profile.
  • IV administration for acute control is performed in a setting with continuous ECG monitoring, starting with an initial weight-based bolus (e.g., 0.25 mg/kg), followed by a short-term continuous infusion (e.g., 5 mg/hour).

Recent Clinical Evidence

Anotrit is a trade name for a topical formulation of Diltiazem hydrochloride, a calcium channel blocker. The medication is used to promote the healing of chronic anal fissures and reduce the associated pain. Clinical research focuses on its efficacy as a non-surgical alternative to procedures like lateral internal sphincterotomy.

Efficacy and Safety Profile

Studies have assessed the effectiveness of topical Diltiazem in comparison to placebo and other pharmacological treatments, primarily topical glyceryl trinitrate (GTN).

  • Healing Rates: Multiple randomized controlled trials and systematic reviews indicate that topical Diltiazem is generally comparable to topical GTN in achieving fissure healing. Although some early reviews suggested only marginal superiority to placebo, more recent analyses position it as an effective treatment, with healing rates often reported between 48% and 71% over several weeks.
  • Pain Reduction: Clinical trials consistently demonstrate that Diltiazem effectively reduces anal fissure-related pain, including the average worst pain experienced during or following defecation.
  • Recurrence: Some systematic reviews suggest that Diltiazem may be associated with a lower rate of fissure recurrence compared to GTN.

Comparative Adverse Events

One of the primary benefits highlighted in clinical comparisons is the favorable side effect profile of topical Diltiazem compared to topical nitrates (GTN). The table below summarizes key differences in common adverse events:

Adverse Event Topical Diltiazem Topical Glyceryl Trinitrate (GTN)
Headache Low Incidence High Incidence
Local Symptoms Local burning, itching (minor) Minimal

Topical Diltiazem is associated with a significantly lower incidence of headache compared to GTN. This distinction can improve patient adherence to the treatment regimen, making it a preferred option for individuals who are sensitive to the systemic side effects of nitrates. Current clinical guidelines frequently recommend topical calcium channel blockers as a first-line pharmacological treatment for chronic anal fissure.

Key Studies & References

  1. Topical diltiazem versus topical glyceryl trinitrate in the treatment of chronic anal fissure: a prospective comparative study

Frequently Asked Questions (FAQ)

Common questions about Anotrit (FAQ)

Q: What is the main reason Anotrit is prescribed?

A: Anotrit is the trade name for Diltiazem, a medication that is FDA-approved for several cardiovascular conditions. Its main purpose is to treat chronic stable angina (chest pain), hypertension (high blood pressure), and certain types of cardiac arrhythmias (irregular heart rhythms), such as atrial fibrillation.

Q: Is Anotrit used for anything besides the main condition it treats?

A: Yes, in addition to its approved uses for cardiovascular conditions, the active ingredient Diltiazem is sometimes used in specific, compounded forms. Official information notes that topical preparations of Diltiazem are used off-label to treat chronic anal fissures. It may also be used in some cases for the prevention of migraines.

Q: How quickly do people typically start seeing the expected effects of Anotrit?

A: While the drug begins to act on the body on the day it is first taken, the maximum desired therapeutic effect often takes time to develop. According to regulatory labeling, the full effect, particularly for managing high blood pressure, is typically observed after about 14 days of continuous use. Dose adjustments are generally made by a healthcare provider based on this timeframe.

Q: Does Anotrit need to be taken at the same time every day?

A: Yes, the extended-release forms of this medication are designed for once-daily use. Taking the medication at the same time each day, as directed by your prescription label, is important for helping to maintain a consistent level of the drug in the bloodstream throughout the day.

Q: What happens if I stop taking Anotrit suddenly?

A: Regulatory warnings specifically caution against stopping the medication suddenly. Abrupt discontinuation of Diltiazem may lead to rebound effects, such as a rapid increase in blood pressure or a worsening of chest pain. This can, in turn, increase the risk of serious cardiovascular events like a heart attack or stroke.

Q: Is it normal to feel a mild headache when first starting Anotrit?

A: Headache is one of the most commonly reported adverse reactions associated with Anotrit, occurring in a significant number of users during clinical studies. It is described as a common side effect in the regulatory adverse reaction lists. Official information advises contacting a healthcare professional if any side effect, including a headache, is severe or persistent.

Q: Are there any long-term research themes associated with Anotrit use?

A: Yes, research themes extend beyond short-term drug actions. Official data and studies have examined the long-term effectiveness of Diltiazem, particularly in patients with chronic stable angina (chest pain). These studies evaluate sustained benefits, such as the drug's effect on exercise tolerance and cardiac function over a period of several months.

Q: Are there known interactions between Anotrit and common vitamins or supplements?

A: The regulatory documents advise general caution because Diltiazem can interact with other medicines, vitamins, or herbal products. The label specifically mentions an interaction with the herbal product St. John’s Wort, which can decrease Diltiazem’s levels. It is important for patients to discuss all products, including vitamins and supplements, with their healthcare provider.

Q: Does Anotrit contain any ingredients that might cause an allergic reaction?

A: Yes. Official prescribing information states that Anotrit should not be used if you have a known history of hypersensitivity or allergic reaction to the active ingredient, Diltiazem hydrochloride, or any of its inactive components (excipients). Any known allergy should be discussed with the prescribing healthcare provider.

Q: Why do some sources refer to Anotrit with a different name?

A: Anotrit is a specific brand name given to the medication by its manufacturer. The active substance responsible for the therapeutic effect is Diltiazem hydrochloride. This active ingredient is also available under its generic name (Diltiazem) and numerous other brand names, depending on the country and formulation.

Q: What should be done if an interaction with another medicine is suspected?

A: If you suspect you are experiencing an interaction between Anotrit and another product, official guidance recommends immediate consultation with a healthcare provider or pharmacist. A professional can assess the situation and provide necessary advice on how to proceed.

Q: Is it possible for side effects to appear long after starting Anotrit?

A: Yes, while some adverse effects, such as acute liver injury, are often reported in the first few weeks of therapy, the potential for other issues exists over time. Official warnings advise that lab parameters should be monitored at regular intervals for as long as the medication is prescribed.

Q: Is there a generic version of Anotrit described in official materials?

A: Yes. The active ingredient, Diltiazem hydrochloride, is widely available as a generic medication. Official U.S. formularies and drug listings describe Diltiazem as a substance available in various generic and brand-name forms.

Q: Does Anotrit have a potential interaction with alcohol?

A: Yes, Diltiazem has a documented interaction with alcohol. Alcohol consumption may increase the drug’s blood pressure-lowering effect. This may significantly increase the risk of side effects like severe dizziness, lightheadedness, or fainting (orthostatic hypotension).

Q: Are there official warnings about operating machinery while using Anotrit?

A: Yes. Official patient information includes warnings about performing activities that require alertness. Regulatory information advises caution regarding driving or operating machinery until the patient understands the drug's effects, due to the potential for dizziness or drowsiness.

Q: How long does it usually take for Anotrit to be completely cleared from the body?

A: The active drug's presence in the bloodstream is defined by its elimination half-life, which is the time it takes for half the dose to be removed. For Diltiazem, this half-life ranges from approximately 3 to 9 hours, depending on the formulation. Complete clearance from the body, including all non-active breakdown products, takes longer.

Q: Is Anotrit included in the official lists of essential medicines?

A: Yes, the active ingredient Diltiazem is recognized by various governmental health bodies. It is included on official national formularies, such as the VA National Formulary in the United States, which list drugs considered important for patient care.

Q: What are the high-level themes of recent research on Anotrit?

A: Research themes primarily focus on Diltiazem’s established roles as a heart rhythm regulator (anti-arrhythmic) and a treatment for chest pain (anti-anginal). Studies examine its impact on improving exercise tolerance and include investigation into its use in treating non-cardiovascular conditions, such as anal fissures.

Q: How does Anotrit interact with birth control pills?

A: Diltiazem can potentially affect the metabolism of certain oral contraceptives. Regulatory interaction data indicates that it may increase the blood levels and effects of birth control pills that contain components like ethinyl estradiol and norethindrone. Decisions regarding monitoring or dose adjustment are made by the healthcare provider.

Q: Does Anotrit cause sun sensitivity, as noted in official warnings?

A: Sun sensitivity, or photosensitivity, is considered a rare but possible adverse reaction to Diltiazem. Case reports published in NIH-linked journals emphasize the importance of recognizing this potential skin reaction. If a patient develops a rash or increased sensitivity to sun exposure, regulatory guidance suggests consulting a healthcare provider.

Q: Is Anotrit typically used for a short time or long-term?

A: Anotrit is generally prescribed for the long-term management of chronic conditions, such as high blood pressure and angina. It is intended to control these conditions over time and is not considered a cure. The dosage schedule for extended-release forms is designed to support prolonged therapy.

Q: What is the purpose of the black box warning on Anotrit (if applicable)?

A: The U.S. Food and Drug Administration (FDA) assigns a Black Box Warning to highlight serious or life-threatening risks. According to current official labeling, Diltiazem hydrochloride does not carry an FDA Black Box Warning.

Q: How do regulatory agencies describe the efficacy data for Anotrit?

A: Regulatory agencies consider Diltiazem effective based on the results of clinical trials. Efficacy data demonstrate the drug's ability to significantly reduce blood pressure, decrease the frequency and severity of angina attacks, and effectively control certain rapid heart rhythms (arrhythmias).

Q: Is Anotrit safe for people with diabetes?

A: Official patient cautions note that Anotrit should be used with careful consideration in people with diabetes. Diltiazem may influence blood glucose levels, and as a result, careful monitoring of blood sugar may be required for diabetic patients during treatment.

Q: What are the general expectations for a follow-up appointment after starting Anotrit?

A: Follow-up appointments are expected to ensure the medication is working as intended and to monitor for safety. Regulatory information specifies the need for monitoring the drug’s effects on blood pressure and heart rate, as well as checking lab parameters such as liver and kidney function, especially during the initial weeks of therapy.

How should Anotrit be stored and disposed of?

Official Storage and Disposal Requirements

Anotrit must be stored at Controlled Room Temperature, specifically between 20°C to 25°C (68°F to 77°F). Storage excursions are permitted between 15°C and 30°C (59°F and 86°F).

Protection and Packaging The medicine must be kept in its original container with the cap tightly closed. The container must be protected from light and excessive moisture to maintain stability. Anotrit must be stored out of the sight and reach of children at all times.

Disposal Instructions Disposal of unused or expired Anotrit must align with local and national regulations. The preferred method is typically a drug take-back program. The official guidance specifies that the substance must not be allowed to enter sewers, surface water, or ground water.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anotrit found in:

A-Z Index: